12/3
04:32 pm
otlk
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/24
09:05 am
otlk
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Medium
Report
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
11/21
02:04 pm
otlk
Oncobiologics (NASDAQ:OTLK) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
08:30 am
otlk
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Medium
Report
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
11/3
08:35 am
otlk
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
Neutral
Report
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
10/31
01:04 pm
otlk
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/30
08:05 am
otlk
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "neutral" rating reaffirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock.
9/29
08:52 am
otlk
Outlook Therapeutics Provides Update on Type A Meeting with FDA [Yahoo! Finance]
High
Report
Outlook Therapeutics Provides Update on Type A Meeting with FDA [Yahoo! Finance]
9/29
08:45 am
otlk
Outlook Therapeutics Provides Update on Type A Meeting with FDA
Medium
Report
Outlook Therapeutics Provides Update on Type A Meeting with FDA
9/22
08:08 am
otlk
Oncobiologics (NASDAQ:OTLK) had its price target lowered by analysts at Ascendiant Capital Markets from $21.00 to $8.00. They now have a "buy" rating on the stock.
Low
Report
Oncobiologics (NASDAQ:OTLK) had its price target lowered by analysts at Ascendiant Capital Markets from $21.00 to $8.00. They now have a "buy" rating on the stock.